HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Helena A. Yu(Memorial Sloan Kettering Cancer Center), Pasi A. Jänne(Harvard University), David Sternberg(Daiichi Sankyo (United States)), Benjamin Besse(Institut Gustave Roussy), Erminia Massarelli(The University of Texas MD Anderson Cancer Center), Jyoti D. Patel(Memorial Sloan Kettering Cancer Center), Yasushi Goto(Tennessee Oncology), Paolo Bironzo(University of Turin), Pomy Shrestha(Daiichi Sankyo (United States)), Hidetoshi Hayashi(Kindai University), Pang‐Dian Fan(Daiichi Sankyo (United States)), Melissa L. Johnson(Tennessee Oncology), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Kiyotaka Yoh(National Cancer Center Hospital East), James Chih‐Hsin Yang(National Taiwan University Hospital), Martin Reck(German Center for Lung Research), Dalila Sellami(Daiichi Sankyo (United States)), Se‐Hoon Lee(Samsung Medical Center), Toshiyuki Kozuki(Shikoku Cancer Center), Steven Kao(Chris O’Brien Lifehouse), Andrea Sporchia(Daiichi Sankyo (United States)), Thomas John(Austin Hospital), Enriqueta Felip(Institut Català d'Ornitologia), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Dong‐Wan Kim(Seoul National University Hospital), Qian Dong(Daiichi Sankyo (United States)), Parul Patel(Daiichi Sankyo (United States)), Egbert F. Smit(Dutch Cancer Society)
Cited by 224
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k